IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$66.32 USD
+1.36 (2.09%)
Updated May 13, 2024 04:00 PM ET
After-Market: $66.35 +0.03 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.32 USD
+1.36 (2.09%)
Updated May 13, 2024 04:00 PM ET
After-Market: $66.35 +0.03 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
by Zacks Equity Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season?
by Zacks Equity Research
Intra-Cellular (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -12.66% and 58.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 16.67% and 483.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Diversify Your Portfolio With a New Psychedelic Drug ETF
by Sweta Jaiswal, FRM
A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.
Strength Seen in Intra-Cellular (ITCI): Can Its 9.8% Jump Turn into More Strength?
by Zacks Equity Research
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Company News for Dec 21, 2021
by Zacks Equity Research
Companies in the news are: ITCI, VRS, CANF, FSM
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Sep 28, 2021
by Zacks Equity Research
Companies in the news are: BYND, RCAT, ITCI, NNVC
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -7.59% and 8.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Intra-Cellular Therapies (ITCI) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Intra-Cellular Therapies (ITCI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 10.59% and 0.06%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?